Cyclin e and histone H3 levels are regulated by 5-fluorouracil in a DNA mismatch repair-dependent manner

Cancer Biology and Therapy

Volumn 10, Issue 11, 2010, Pages 1147-1156

  Chung, Heekyung ^a   Chaudhry, Joy ^a   Lopez, Claudia G ^a   Carethers, John M ^a,b,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

5 fluorouracil; Cancer treatment; Colorectal cancer; Cyclin E; DNA mismatch repair; Histone H3; Microsatellite instability

Indexed keywords

CYCLIN B1; CYCLIN B2; CYCLIN E; FLUOROURACIL; HISTONE H2A; HISTONE H2B; HISTONE H3; MISMATCH REPAIR PROTEIN PMS2; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE P60; PROTEIN P53;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; DOWN REGULATION; ENZYME ACTIVATION; EXCISION REPAIR; HUMAN; HUMAN CELL; MISMATCH REPAIR; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIMETABOLITES, ANTINEOPLASTIC; CELL CYCLE; COLORECTAL NEOPLASMS; CYCLIN E; DNA DAMAGE; DNA MISMATCH REPAIR; FLUOROURACIL; GENE EXPRESSION; HCT116 CELLS; HISTONES; HT29 CELLS; HUMANS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

EID: 78649891006     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.11.13447     Document Type: Article

References (48)

1. Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo. Clinic J Clin Oncol 1989; 7:1447-56.
2. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322:352-8.
3. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122:321-6.
4. Boland CR, Sinicrope FA, Brenner DE, Carethers JM. Colorectal cancer prevention and treatment. Gastroenterology 2000; 118:115-28.
5. Cancer Meta-Analysis Groups. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16:301-8.
6. Carethers JM, Chung H, Tajima A. Mismatch repair competency predicts 5-Fluorouracil effectiveness on patient survival. In: Intestinal Inflammation and Colorectal Cancer. Prceedings of Falk Symposium #158. Dordrecht. The Netherlands: Springer Publishers 2007; 72-84.
7. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349:247-57.
8. Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 2004; 126:394-401.
9. Palombo F, Iaccarino I, Nakajima E, Ikejima M, Shimada T, Jiricny J. hMutS-beta, a heterodimer of hMSH2 and hMSH3, binds to insertion/deletion loops in DNA. Curr Biol 1996; 6:1181-4.
10. Modrich P. Mechanisms in eukaryotic mismatch repair. J Biol Chem 2006; 281:30305-9.
11. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 2008; 135:1079-99.
12. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993; 75:1027-38. (Pubitemid 24014559)
13. Akiyama Y, Sato H, Yamada T, Nagasaki H, Tsuchiya A, Abe R, et al. Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res 1997; 57:3920-3.
14. Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM, et al. Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature 1994; 371:75-80. (Pubitemid 24277467)
15. Papadopoulos N, Nicolaides NC, Wei YF, Ruben SM, Carter KC, Rosen CA, et al. Mutation of a mutL homolog in hereditary colon cancer. Science 1994; 263:1625-9.
16. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998; 95:6870-5.
17. Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci USA 1998; 95:8698-702. (Pubitemid 28350551)
18. Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 2006; 55:848-55.
19. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999; 117:123-31.
20. Tajima A, Hess MT, Cabrera BL, Kolodner RD, Carethers JM. The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology 2004; 127:1678-84. (Pubitemid 39575846)
21. Meyers M, Wagner MW, Mazurek A, Schmutte C, Fishel R, Boothman DA. DNA mismatch repair-dependent response to fluoropyrimidine-generated damage. J Biol Chem 2005; 280:5516-26. (Pubitemid 40280029)
22. 2 cell cycle checkpoint. Cancer Res 1995; 55:3721-5.
23. Carethers JM, Hawn MT, Chauhan DP, Luce MC, Marra G, Koi M, et al. Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N′-nitro-N-nitrosoguanidine. J Clin Invest 1996; 98:199-206. (Pubitemid 26243837)
24. Kat A, Thilly WG, Fang WH, Longley MJ, Li GM, Modrich P. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc Natl Acad Sci USA 1993; 90:6424-8.
25. Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY, et al. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 1999; 13:152-7.
26. Hickman MJ, Samson LD. Apoptotic signaling in response to a single type of DNA lesion, O(6)-methylguanine. Mol Cell 2004; 14:105-16.
27. 2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. Genes Dev 2004; 18:1331-44.
28. Remick SC, Grem JL, Fischer PH, Tutsch KD, Alberti DB, Nieting LM, et al. Phase I trial of 5-fluorouracil and dipyridamole administered by seventy-two-hour concurrent continuous infusion. Cancer Res 1990; 50:2667-72.
29. Aquilina G, Crescenzi M, Bignami M. Mismatch repair, G(2)/M cell cycle arrest and lethality after DNA damage. Carcinogenesis 1999; 20:2317-26.
30. 2-M cell cycle arrest. Int J Oncol 2005; 26:1653-61.
31. Takahashi Y, Nagata T, Ishii Y, Ikarashi M, Ishikawa K, Asai S. Upregulation of vitamin D3 upregulated protein 1 gene in response to 5-fluorouracil in colon carcinoma SW620. Oncol Rep 2002; 9:75-9.
32. Mariadason JM, Arango D, Shi Q, Wilson AJ, Corner GA, Nicholas C, et al. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 2003; 63:8791-812. (Pubitemid 38064059)
33. Clarke PA, George ML, Easdale S, Cunningham D, Swift RI, Hill ME, et al. Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling. Cancer Res 2003; 63:6855-63.
34. De Angelis PM, Kravik KL, Tunheim SH, Haug T, Reichelt WH. Comparison of gene expression in HCT116 treatment derivatives generated by two different 5-fluorouracil exposure protocols. Mol Cancer 2004; 3:11.
35. Matsuyama R, Togo S, Shimizu D, Momiyama N, Ishikawa T, Ichikawa Y, et al. Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. Int J Cancer 2006; 119:406-13.
36. Xi Y, Nakajima G, Schmitz JC, Chu E, Ju J. Multilevel gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer. BMC Genomics 2006; 7:68.
37. Hemminki A, Mecklin JP, Jarvinen H, Aaltonen LA, Joensuu H. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000; 119:921-8.
38. Elsaleh H, Powell B, Soontrapornchai P, Joseph D, Goria F, Spry N, et al. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma. Oncology 2000; 58:52-9.
39. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000; 355:1745-50.
40. Yoshikawa R, Kusunoki M, Yanagi H, Noda M, Furuyama JI, Yamamura T, et al. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 2001; 61:1029-37.
41. 1/S arrest in laryngeal squamous cell carcinoma via a p53-independent pathway. Cancer J 2006; 12:482-93.
42. Lim YJ, Rhee JC, Bae YM, Chun WJ. Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells. World J Gastroenterol 2007; 13:1947-52.
43. Matuo R, Sousa FG, Escargueil AE, Grivicich I, Garcia-Santos D, Chies JA, et al. 5-Fluorouracil and its active metabolite FdUMP cause DNA damage in human SW620 colon adenocarcinoma cell line. J Appl Toxicol 2009; 29:308-16.
44. 1 checkpoint pathway. EMBO J 2004; 23:1133-43.
45. Lafon-Hughes L, Di Tomaso MV, Mendez-Acuna L, Martinez-Lopez W. Chromatin remodelling mechanisms in cancer. Mutat Res 2008; 658:191-214.
46. Bartova E, Krejci J, Harnicarova A, Galiova G, Kozubek S. Histone modifications and nuclear architecture: a review. J Histochem Cytochem 2008; 56:711-21. (Pubitemid 351991084)
47. Bhaumik SR, Smith E, Shilatifard A. Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol 2007; 14:1008-16. (Pubitemid 350060343)
48. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, Kunkel TA, et al. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 1994; 54:4308-12. (Pubitemid 24273140)